panCELLa’s intent to develop therapeutic products in the mesenchymal stem cell (MSC) and pancreatic islet space has recently led to the creation of Implant Therapeutics. Implant Therapeutics, under the guidance of D...
Licenses aim to accelerate drug discovery leading to development of new therapies PanCELLa agreement marks MilliporeSigma’s first CRISPR license for bioproduction “MilliporeSigma’s latest CRISPR licenses are th...
The inventors of panCELLa's exclusive induced Allogeneic Cell Tolerance have recently published a letter in CellStemCell. This letter is in response to Bryan J. González, et. all's "How Safe Are Universal Pluripotent...